Sponsors

Aiosyn launches kidney image analysis services via NephroPath platform

Aiosyn, a medical software company specialising in AI-powered pathology solutions for cancer and kidney disease, has announced the introduction of its NephroPath platform. By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of chronic kidney disease (CKD) therapies using new and quantitative insights offered through Nephropath’s kidney image analysis services.

The NephroPath platform provides computational pathology algorithms for a detailed evaluation of histological biomarkers in kidney biopsies, including segmentation of main tissue classes, quantification of interstitial fibrosis, precise localisation and quantification of glomeruli, and more. These AI-powered analyses effectively overcome the constraints of current semi-quantitative scoring systems, which are often based on subregions of the kidney and are subject to observer variability.

NephroPath’s AI-based quantification provides reproducible, consistent, fast, and more detailed scoring of renal pathology (imaging) biomarkers in preclinical and clinical specimens compared to human reading. This can accelerate preclinical and clinical development projects. The algorithms will also be instrumental in new CKD biomarker discovery projects.

Through Nephropath’s kidney image analysis services, Aiosyn offers whole kidney quantification and custom kidney analyses. Aiosyn’s data-rich analysis derived from slide data provides per-slide tissue quantifications and detailed dataset characterisation. Findings are delivered in a comprehensive image analysis report, including biomarker scores and visual results.

“Using Aiosyn's NephroPath platform we provide researchers with a new and powerful technique to complement the CKD drug development toolbox,” said Patrick de Boer, CEO of Aiosyn.

CKD is forecasted to grow to the fifth predominant cause of mortality by 2040, and with over 90 new CKD therapies in development, there is a need for advanced tools that can accelerate drug development and enhance diagnostic accuracy.

In a recent preclinical study, conducted in collaboration with a leading preclinical research organisation (CRO), the NephroPath platform demonstrated its effectiveness in segmenting kidney tissue classes and quantifying glomerulosclerosis and tubular damage on whole rat kidneys. A positive correlation was observed between the glomerulosclerosis and tubular scores and kidney damage across all groups. The study abstract will be presented at the upcoming CKD Summit in Boston (19-21 March).

The illustration above demonstrates the NephroPath platform’s capabilities in performing automated quantification and multi-class prediction on an entire rat kidney cortex. Notable classes: normal tubules (orange), atrophic/dilated tubules (green/red), glomeruli (pink), abnormal/sclerotic glomeruli (dark blue), arteries (light blue), interstitium (not coloured). (Photo: Business Wire)

The NephroPath platform is for research use only and should not be used for diagnostic procedures.

 

Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024